ClinicalTrials.gg
TerminatedNCT03786081Updated Jul 22, 2026

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

A Phase 1/2 interventional study of Tisotumab Vedotin and Bevacizumab in Cervical Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Terminated at 71 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor has decided to stop the trial based on strategic decisions

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
214
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Uterine Cervical Neoplasms by Pfizer — 3 open to participants now, 4 under way, none of them phase 3. Uterine Cervical Neoplasms · Pfizer.

Enrollment
4th of 16
214 · median 122
Started
2019
the only one that year
Phase 1/2
3 of 17
none open now
Registered
7th of 17
by date

Among the 17 studies in Uterine Cervical Neoplasms by Pfizer, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 1/2, and was the 7th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

3 of the 17 studies in Uterine Cervical Neoplasms by Pfizer are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Uterine Cervical Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer.

The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.

Read the detailed description

The dose escalation part will occur in participants with cervical cancer who have progressed during or after standard of care therapy and who are intolerant or ineligible to receive standard of care treatments. Arm A will be conducted by escalating doses of both tisotumab vedotin and bevacizumab. Dose escalations of the tisotumab vedotin + pembrolizumab and tisotumab vedotin + carboplatin combinations (Arms B and C, respectively) will be conducted by combining fixed doses of either pembrolizumab or carboplatin with increasing doses of tisotumab vedotin.

The dose expansion part of this study (Arms D through H) will be conducted in 2 populations: participants with cervical cancer who have not received prior systemic therapy for recurrent or stage IVB cervical cancer (Arms D, E, and H) and participants with cervical cancer who have progressed on or after at least 1 but no more than 2 prior systemic therapies (Arms F and G).

Participants enrolled to Arms D, E, F and H will receive the RP2D of tisotumab vedotin established in the dose escalation part. Participants enrolled to Arm G will receive tisotumab vedotin weekly (at a dose lower than subjects in all other Arms) for three weeks and 1 week off (28-day treatment cycle).

03

Conditions studied

  • Cervical Cancer

Keywords

  • cervical carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on or after standard of care treatments or are ineligible or intolerant to standard of care for recurrent or stage IVB cervical cancer (Arms A, B and C only).
  • Must have squamous, adenosquamous, or adenocarcinoma of the cervix and must not have received prior systemic therapy for recurrent or stage IVB cervical cancer (Arms D, E, and H only).
  • Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on or after at least one but no more than two prior systemic therapies for recurrent or stage IVB cervical cancer (Arms F and G only).
  • Must have baseline per v1.1.
  • Have an (ECOG) performance status of 0 or 1 (All Arms).
  • Is not pregnant, breastfeeding, or expecting to conceive children within the projected duration of the trial and for at least 6 months after the last trial treatment administration
  • Participants of must agree to use adequate during and for 6 months after the last dose of trial treatment administration.
  • Must sign an form (ICF) indicating the trial subject understands the purpose of and procedures required for the trial and are willing to participate in the trial (All Arms).

Exclusion criteria

Exclusion Criteria:

  • Has bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage. (All Arms)
  • Has clinical signs or symptoms of gastrointestinal obstruction and requires parenteral hydration and/or nutrition. Post-operative obstructions within 4 weeks of abdominal surgery are permitted. (All Arms)
  • Has clinically significant bleeding issues or risks

    • Prior history (within 3 months) or current evidence of hemoptysis (1/2 teaspoon or more) (Arm A and bevacizumab-eligible participants in Arm H)
    • Recent (within 4 weeks of first dose of trial treatment) clinically significant gastrointestinal or vaginal bleeding requiring PRBC transfusion (Arms A and H only)
    • Recent (within 4 weeks of first dose of trial treatment) evidence of wound healing complications that require medical intervention (Arms A and H only)
  • Has active ocular surface disease at baseline. Subjects with prior history of cicatricial conjunctivitis are ineligible (All Arms).
  • Clinically significant cardiac disease
  • Requires anti-coagulation therapy (Arms A and H only)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    A: Tisotumab Vedotin + bevacizumab

    Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients

    Drug: Tisotumab Vedotin · Drug: Bevacizumab

  • Experimental
    B: Tisotumab vedotin + pembrolizumab

    Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients

    Drug: Tisotumab Vedotin · Drug: Pembrolizumab

  • Experimental
    C: Tisotumab vedotin + carboplatin

    Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients

    Drug: Tisotumab Vedotin · Drug: Carboplatin

  • Experimental
    D: Tisotumab vedotin + carboplatin

    Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients

    Drug: Tisotumab Vedotin · Drug: Carboplatin

  • Experimental
    E: Tisotumab vedotin + pembrolizumab

    Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients

    Drug: Tisotumab Vedotin · Drug: Pembrolizumab

  • Experimental
    F: Tisotumab vedotin + pembrolizumab

    Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients

    Drug: Tisotumab Vedotin · Drug: Pembrolizumab

  • Experimental
    G: Tisotumab vedotin monotherapy

    Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.

    Drug: Tisotumab Vedotin

  • Experimental
    H: Tisotumab vedotin + pembrolizumab + carboplatin +/- bevacizumab

    Dose expansion: Tisotumab vedotin in combination with pembrolizumab and carboplatin with or without bevacizumab once every three weeks in previously untreated patients

    Drug: Tisotumab Vedotin · Drug: Bevacizumab · Drug: Pembrolizumab · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Dose escalation: Dose Limiting Toxicities (DLTs)

    To establish the MTD and RP2D of tisotumab vedotin in combination

    Time frame: DLTs will be identified during the first treatment cycle (21 day cycles)

  2. Dose expansion: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Objective response is defined as confirmed partial response (PR) or complete response (CR)

    Time frame: approximately 2 years

Secondary outcomes

  1. Number of adverse events (AEs)

    Any untoward medical occurrence in a clinical trial participant whether or not considered related to the medicinal product.

    Time frame: up to 2 years

  2. Dose escalation: ORR per RECIST v1.1

    Objective response is defined as confirmed PR or CR.

    Time frame: approximately 2 years

  3. Duration of Response (DOR) per RECIST v1.1 by investigator assessment

    Will be calculated from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease (PD) or death.

    Time frame: approximately 2 years

  4. Time to Response (TTR) per RECIST v1.1 by investigator assessment

    Will be calculated from the date of the first dose to the date of the initial documentation of response (CR or PR).

    Time frame: approximately 2 years

  5. Progression free survival (PFS) per RECIST v1.1 by investigator assessment

    The time from the date of the first trial drug administration to the date of the first documented disease progression or death due to any cause.

    Time frame: approximately 2 years

  6. Overall Survival (OS)

    The time from the date of the first trial drug administration to the date of death due to any cause.

    Time frame: approximately 2 years

  7. Maximum concentration (Cmax) (All Arms except G)

    Pharmacokinetic (PK) parameter

    Time frame: Up to 42 days

  8. Cmax (Arm G only)

    PK parameter

    Time frame: Up to 2 years

  9. Trough Concentration (Ctrough) (All Arms)

    PK parameter

    Time frame: Up to 2 years

  10. Area under the concentration-time curve (AUC) (All Arms except G)

    PK parameter

    Time frame: Through 21 days after first dose

  11. AUC (Arm G only)

    PK parameter

    Time frame: Through 8 days after first dose

  12. Anti-drug antibodies (ADAs)

    Time frame: Up to 2 years

07

Study locations

71 sites
  • Arizona Oncology Associates
    Phoenix, Arizona 85016, United States
  • Univ California, Irvine Medical Center
    Orange, California 92868, United States
  • Olive View - UCLA Research and Education Institute
    Sylmar, California 91342, United States
  • Baptist MD Anderson Cancer Center
    Jacksonville, Florida 32207, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • University of Chicago
    Chicago, Illinois 60525, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center
    Westwood, Kansas 66205, United States
  • Oschner Clinic
    New Orleans, Louisiana 70121, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Billings Clinic Cancer Center
    Billings, Montana 59101, United States
  • Montana Cancer Consortium
    Billings, Montana 59102, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of North Carolina Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • University of Cincinnati Physicians Group
    Cincinnati, Ohio 45206, United States
  • Cleveland Clinic
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University Wexner Medical Center
    Hilliard, Ohio 43026, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Brown University - Women's and Infant Hospital
    Providence, Rhode Island 02905, United States
  • St Francis Hospital Cancer Center
    Greenville, South Carolina 29607, United States
  • Huntsman Cancer Center
    Salt Lake City, Utah 84112, United States
  • Carilion Clinic
    Roanoke, Virginia 24016, United States
  • AZ Sint-Jan
    Bruges, 8000, Belgium
  • Cliniques universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Grand Hôpital de Charleroi
    Charleroi, 6000, Belgium
  • Universitair Ziekenhuis Antwerpen (UZA)
    Edegem, 2650, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Universitaire Ziekenhuizen Leuven,
    Leuven, Belgium
  • Centre Hospitalier de l'Ardenne
    Libramont, 6800, Belgium
  • Centre Hospitalier Universitaire (CHU) de Liège
    Liège, 4000, Belgium
  • Grand Hôpital de Charleroi
    Loverval, 6280, Belgium
  • CHU UCL Namur
    Namur, 5000, Belgium
  • Sainte-Elisabeth
    Namur, 5000, Belgium
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 77520, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava-Poruba, 70852, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Prague, 128 51, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Prague, 12851, Czechia
  • Fakultni nemocnice Bulovka
    Prague, 180 81, Czechia
  • Nemocnice Na Bulovce
    Prague, 18081, Czechia
  • Rigshospitalet
    Copenhagen, 5072, Denmark
  • Cork University Hospital
    Cork, Ireland
  • Mater Misericordiae University Hospital
    Dublin, D07 R2WY, Ireland
  • Waterford Regional Hospital
    Waterford, X91 ER8E, Ireland
  • University Hospital Waterford
    Waterford, Ireland
  • Azienda Ospedaliera Cannizzaro
    Catania, 95100, Italy
  • IEO Istituto Europeo di Oncologia
    Milan, 20141, Italy
  • Istituto Nazionale Tumori Fondazione G. Pascale
    Naples, 80131, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 00168, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Rome, 00168, Italy
  • Amsterdam UMC, Locatie AMC
    Amsterdam, 1105 AZ, Netherlands
  • AMC Medical Research
    Amsterdam, Netherlands
  • Universitair Medisch Centrum Groningen (UMCG)
    Groningen, 9713 GZ, Netherlands
  • Radboudumc
    Nijmegen, 6525 GA, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 CC, Netherlands
  • Erasmus University Medical Center Rotterdam
    Rotterdam, 3015, Netherlands
  • UMC Utrecht
    Utrecht, 3508 GA, Netherlands
  • University Medical Center Utrecht (UMC Utrecht)
    Utrecht, 3584, Netherlands
  • Hospital Universitari Vall d'Hebron
    Barcelona, 8035, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital Universitario Virgen de la Arrixaca
    El Palmar, 30120, Spain
  • Hospital 12 De Octubre
    Madrid, 28041, Spain
  • Baskent University Adana Application and Research Center
    Adana, 01220, Turkey (Türkiye)
  • Baskent University Ankara Hospital
    Ankara, 06490, Turkey (Türkiye)
  • Velindre Cancer Centre
    Cardiff, South Glamorgan CF14 2TL, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, Strathclyde G12 OYN, United Kingdom
  • Royal Marsden Hospital- Sutton
    Sutton, Surrey SM2 5PT, United Kingdom
08

References and documents

Publications

  • Van Nieuwenhuysen E, Vergote I, Randall LM, Tromp J, Lorusso D, O'Cearbhaill RE, Boere I, Pisano C, Sanchez LM, Banerjee S, Collins DC, Zikan M, Mathews C, Kummel J, Melichar B, Jackson AL, Madsen K, Gennigens C, Ottevanger N, Ghamande S, Salutari V, Baurain JF, Reyners AKL, Chisamore M, Conte U, Windfeld K, Geiger M, Hansen H, Denys H, Cibula D, Oaknin A, Van Gorp T, Monk BJ; innovaTV 205/ENGOT-cx8/GOG-3024 investigators. Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study. Gynecol Oncol. 2026 Apr;207S:3-13. doi: 10.1016/j.ygyno.2026.02.008. PubMed 42000372 ↗
  • Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, Collins DC, Banerjee S, Mathews CA, Gennigens C, Cibula D, Tewari KS, Madsen K, Kose F, Jackson AL, Boere IA, Scambia G, Randall LM, Sadozye A, Baurain JF, Gort E, Zikan M, Denys HG, Ottevanger N, Forget F, Mondrup Andreassen C, Eaton L, Chisamore MJ, Viana Nicacio L, Soumaoro I, Monk BJ. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. J Clin Oncol. 2023 Dec 20;41(36):5536-5549. doi: 10.1200/JCO.23.00720. Epub 2023 Aug 31. PubMed 37651655 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Mar 2026, 84 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2018
First posted
Dec 24, 2018
StartActual
Feb 27, 2019
Primary completionActual
Mar 19, 2026
CompletionActual
Mar 19, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03786081
Collaborators
Genmab, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgian Gynaecological Oncology Group, GOG Foundation, Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Dec 24, 2018
Start date
Feb 27, 2019
Primary completion
Mar 19, 2026
Completion
Mar 19, 2026
Last update
Jul 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisotumab vedotin

Start the discussion